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Abstract
Background:  Manipulating apoptotic resistance represents an important strategy for the
treatment of hormone refractory prostate cancer. We hypothesised that the Inhibitor of Apoptosis
(IAP) Proteins may be mediating this resistance and knockdown of cIAP-1, cIAP-2 and XIAP would
increase sensitivity to apoptosis.
Methods: cIAP-1, cIAP-2 and XIAP where knocked down either individually or in combination
using siRNA in androgen independent prostate cancer PC-3 cells as confirmed by real-time PCR
and western blotting. Cells were then treated with TRAIL, Etoposide, or Tunicamycin, and
apoptosis assessed by PI DNA staining. Apoptosis was confirmed with Annexin V labelling and
measurement of PARP cleavage, and was inhibited using the pan-caspase inhibitor, zVAD.fmk.
Clonogenic assays and assessment of ID-1 expression by western blotting were used to measure
recovery and proliferation.
Results: PC-3 are resistant to TRAIL induced apoptosis and have elevated expression of cIAP-1,
cIAP-2 and XIAP. Combined knockdown sensitised PC-3 to TRAIL induced apoptosis, but not to
Etoposide or Tunicmycin, with corresponding increases in caspase activity and PARP cleavage
which was inhibited by ZVAD.fmk. Triple knock down decreased proliferation which was
confirmed by decreased ID-1 expression.
Conclusion: Simultaneous knock down of the IAPs not only sensitised the PC-3 to TRAIL but also
inhibited their proliferation rates and clonogenic survival. The inability to alter sensitivity to other
triggers of apoptosis suggests that this effect is specific for death receptor pathways and knock
down might facilitate immune-surveillance mechanisms to counter cancer progression and, in
combination with therapeutic approaches using TRAIL, could represent an important treatment
strategy.
Background
Prostate cancer is the most common male cancer in the
western world and the second leading cause of death
amongst men. In its initial stages, when confined to the
prostate gland, the disease is treatable and even curable.
However, prostate cancer is often diagnosed when it is no
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longer organ confined, and although this condition is also
initially amenable to treatment, eventually an androgen
independent cancer develops, for which there is currently
no cure.
One of the difficulties in treating prostate cancer is that
cells become highly resistant to cell death. Thus although
depriving an androgen-sensitive tumour of androgen ini-
tially results in cell death by apoptosis, once the tumour is
no longer dependent on androgen for survival, this treat-
ment becomes ineffective [1]. This resistance is also asso-
ciated with resistance to conventional chemotherapeutic
agents. Consequently much of the focus of current
research is on understanding the basis of altered apoptotic
signalling in prostate cancer, in an effort to better under-
stand and target cell death pathways for the treatment of
this disease [2].
It is well established that anti-apoptotic proteins such as
Bcl-2 [3] and Hsp27 [4] are over expressed in prostate can-
cer and contribute to the apoptosis resistant phenotype.
In addition, the proteins of the Inhibitor of Apoptosis
(IAP) Protein family are also over expressed and are
thought to contribute to treatment resistance [5-8]. In
prostate cancer, increased expression of cIAP-1, cIAP-2,
XIAP and survivin have been found in biopsy specimens
from all stages of the disease, suggesting an important role
in development and progression [6]. In addition, altered
expression of IAPs have been reported to contribute to
both anti-androgen [8] and cisplatin [7] resistance in
prostate cancer cell lines.
The pro-survival function of IAPs stems in part from their
ability to bind to and inhibit the activity of caspases. This
is certainly the case for XIAP which directly inhibits cas-
pases -3, -7 and -9 [9]. While cIAP1 and cIAP2 can also
bind caspases this does not always result in caspase inhi-
bition in cell free systems [10], suggesting that IAPs other
than XIAP are not truly inhibitors of caspases. While a
number of reports would suggest that they do not inhibit
caspases directly, there is a growing body of evidence that
IAPs such as cIAP1 and cIAP2 may inhibit caspase activity
and apoptosis in a more indirect manner particularly at
the level of death receptor signalling [11-14].
Several studies have demonstrated that targeting individ-
ual IAPs leads to increased sensitivity of a variety of cancer
types to apoptosis [15-19]. In prostate cancer cells, tar-
geted inhibition of survivin increases sensitivity to fluta-
mide [8] and paclitaxel [20]. XIAP inhibition was reported
to increase sensitivity to cisplatin [21], while an antisense
oligonucleotide targeting XIAP has shown promise in pre-
clinical studies [22]. However, little is known about the
effect of specifically targeting cIAP1 or cIAP2 in prostate
cancer cells. In addition, while a number of studies have
investigated the effects of individual IAP knockdown on
cell survival [15-19], few studies have examined the effect
of combined knockdown of two or more IAPs. This is par-
ticularly important given that increased expression of
multiple IAPs has been observed in cancer biospecimens
[5], suggesting that targeting an individual protein may be
insufficient to alter a tumours sensitivity to cell death-
inducing strategies in vitro or in vivo.
As well as their role in apoptosis inhibition, IAPs have a
number of additional functions. These include a role in
cell cycle regulation [23], differentiation [24], immunity
[25], and ubiquitination and targeting of proteins for deg-
radation [26]. In terms of a pro-survival function that does
not rely on direct apoptosis inhibition, cIAP1 has recently
been implicated as an oncogene whereby it cooperates
with Yap 1 to promote tumourogenesis [27]. Thus IAPs
may have other pro-survival effects in addition to direct
apoptosis inhibition, and the effect of knockdown of sin-
gle or multiple IAPs on cell survival merits further investi-
gation.
In the current study we wished to determine whether IAP
knockdown could sensitise prostate cancer cells to apop-
tosis, and to investigate the relative contribution of cIAP-
1, cIAP-2 and XIAP to this process. As well as an effect on
cell death, the impact of specific inhibition of single or
multiple IAPs on long term survival of prostate cancer
cells was investigated. Here we demonstrate that com-
bined knockdown of either cIAP-1 and XIAP, or all three
IAPs, was required to significantly enhance cytotoxicity in
PC-3 cells. This effect was caspase-dependent and specific
for TRAIL treatment. While IAP knockdown in the absence
of additional treatment did not lead to a detectable
increase in apoptosis, it significantly decreased long-term
survival and proliferation, an effect which was associated
with loss of the proliferation marker ID-1. This study
therefore demonstrates the importance of targeting multi-
ple IAPs to enhance sensitivity to apoptosis-inducing
agents, and demonstrates that even in the absence of an
apoptosis stimulus, tumour cell survival may be inhibited
by targeting a specific combination of IAPs.
Methods
Cell culture and treatment
The human prostate cancer cell line PC-3 was purchased
from the American Type Culture Collection (ATCC) and
maintained in RPMI-1640 medium supplemented with
10% FBS, 50 U/ml penicillin/50 μg/ml streptomycin and
2 mM L-glutamine (Invitrogen). Twenty four hours post
transfection, fresh media was added to cells before treat-
ment with TRAIL (Peprotech), Etoposide, or Tunicamycin
(Sigma). In caspase inhibition experiments zVAD.fmk
(R&D Systems) was added for 1 hour prior to treatment
with TRAIL.Molecular Cancer 2009, 8:39 http://www.molecular-cancer.com/content/8/1/39
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Caspase activity assays
Cells were harvested and pelleted by centrifugation at 200
× g for 5 min, resuspended in ice-cold PBS and centrifuged
for a further 5 min at 200 × g. The pellet was then resus-
pended in a 25 μl volume of PBS, transferred to a microti-
tre plate and snap-frozen. Assay buffer (100 mM HEPES,
10% sucrose, 0.1% CHAPS, 5 mM DTT, 0.0001% NP-40,
pH 7.25) containing 50 μM substrate (DEVD-AMC, Pep-
tide Institute Inc., Japan) was added to samples. Cleavage
of the fluorogenic substrate was measured using a Wallac
1420 Multilabel counter (PerkinElmer life sciences) with
355 nm excitation and 460 nm emission wavelengths.
Protein concentration of samples was determined by the
Bradford method and activity was expressed as change in
fluorescence/min/mg of protein.
Western blot analysis
Cells were harvested, washed once in PBS and lysed in
whole cell lysis buffer (20 mM Hepes pH 7.5, 350 mM
NaCl, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 1%
NP-40, 1 mM NaF and 1 mM Na3VO4, plus cocktail of pro-
tease inhibitors). For PARP westerns cells were lysed in
Urea lysis buffer (7 M Urea, 2 M Thiourea, 2% CHAPS, 1%
DTT, 0.8% Pharmalyte, protease inhibitors). Total cellular
protein was determined by means of the Bradford
method. Equal amounts of protein (20–30 μg) were sub-
jected to SDS polyacrylamide gel electrophoresis on 8–
12% gels before being transblotted onto Immobilin P
(Millipore) membranes. Western blotting was performed
using antibodies to cIAP-1, cIAP-2, XIAP (R&D Systems),
caspase-3, caspase-8, caspase-9 (Cell Signalling Technol-
ogy), PARP (Biomol), ID-1 (Santa Cruz), β-Actin (Sigma)
and GAPDH (Chemicon), followed by incubation with
the appropriate horseradish peroxidase-conjugated sec-
ondary antibodies. Signals were detected using ECL™
(Amersham Biosciences).
Quantification of Apoptosis and Viability
Apoptotic events were described as a percentage of total
events with hypodiploid DNA assessed by propidium
iodide incorporation. Cells were harvested by trypsinisa-
tion, permeabilised with a hypotonic fluorochrome solu-
tion (50 mg/ml PI, 3.4 mM sodium citrate, 1 mM Tris, 0.1
mM EDTA, and 0.1% Triton X-100) and incubated on ice
for 10 min prior to analysis. Samples were run on an Epics
XL-MCL Coulter Elite Cytometer (Coulter Cytometry).
Five thousand events were gated on PI intensity and ana-
lysed using Mplus software.
Real Time PCR
Total RNA was extracted using Trizol reagent (Invitrogen)
using standard procedures. Reverse transcription was car-
ried out with 1 μg total RNA using random primers and
SUPERSCRIPT II (Invitrogen). Real-Time PCR TaqMan
assay was used to quantitate the relative gene expression
levels of cIAP1, cIAP2 and XIAP, with ribosomal 18S gene
used as an endogenous control for normalisation of target
genes. Primers and probes supplied as pre-developed
assay, were combined with Taqman Universal PCR Master
Mix (Applied Biosystems) and cDNA. Amplification was
performed on the ABI 7900 HT Sequence Detection Sys-
tem at default thermal cycling conditions: 2 min at 50°C,
10 min at 95°C, 40 cycles of 15 sec at 95°C, and 1 min at
60°C. Results were analysed using the standard curve
method of analysis.
RNA interference
siRNAs targeting cIAP-1, cIAP-2, XIAP, and Silencer Nega-
tive Control siRNAs were purchased from Ambion. PC-3
cells were seeded in antibiotic-free media for 24 h prior to
transfection with 0.5 nM siRNA targeting cIAP-1, cIAP-2,
XIAP, or combinations thereof, and corresponding non-
targeting controls. A total of 1.5 nM of siRNA was added
to each experiment made up of the target siRNA and
topped up with the appropriate concentration of non-tar-
geted controls where appropriate. Transfections were car-
ried out in OptiMem medium (Gibco) using
Lipofectamine 2000 transfection reagent (Invitrogen).
Twenty four hours post transfection cells were harvested
and assayed for RNA and protein expression levels of the
target of interest. At the same time corresponding samples
were treated as described in the text.
Annexin V staining and flow cytometry
Cells were harvested by trypsinisation, washed in cold
PBS, and resuspended in 100 μl of Annexin V/calcium
binding buffer solution (IQProducts). Following incuba-
tion at RT for 15 min in the dark, samples were placed on
ice and 300 μl of calcium binding buffer and 400 μl of PI-
viability solution were added. Samples were run on an
Epics XL-MCL Coulter Elite Cytometer (Coulter Cytome-
try). A minimum of 104 events were acquired and ana-
lysed using Mplus software.
Crystal violet assay
Following transfection, cells were grown for up to 5 days
in 6 well plates. To determine cell number at each time-
point, cells were fixed in 1% glutaraldehyde solution,
washed, incubated with 1% crystal violet (Sigma-Aldrich,
UK), washed, solubilised with 1% Triton X-100, and ana-
lysed at an absorbance of 590 nm (Tecan UK Ltd., UK) as
previously described [28].
Clonogenic survival assay
Twenty four hours post-transfection cells were trypsinised,
counted, and accurately seeded at densities of 1000 per
well in 6-well plates. Cells were grown for 2 weeks until
colonies were of sufficient size for staining and counting.
Colonies were washed in PBS, stained with fixation-stain-
ing solution (glutaraldehyde 6% (v/v), crystal violet 0.5%Molecular Cancer 2009, 8:39 http://www.molecular-cancer.com/content/8/1/39
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(w/v) in H2O), washed by immersing in tap water and
then air dried at room temperature. Colonies were
counted to determine surviving fraction using the follow-
ing formulae:
Statistical analysis
Statistical analysis was carried out using unpaired student
t-test (Graphpad InStat 3 software, GraphPad Software,
Inc., San Diego). Results were considered statistically sig-
nificant where p < 0.01, and results are expressed as mean
± the standard deviation.
Results
TRAIL induced caspase activation in PC-3 cells does not 
lead to apoptosis
Androgen independent prostate cancer cell lines are
highly resistant to apoptosis inducing agents such as
TRAIL [29]. It is thought that this is due in part to altered
expression of apoptosis regulatory molecules which
impairs apoptotic signalling. In order to investigate at
which point resistance to TRAIL is occurring, PC-3 cells
were treated with TRAIL and caspase activity was meas-
ured at 3 and 6 hours post-treatment. As shown in Figure
1, TRAIL treatment leads to a significant induction of cas-
pase activity as assessed by DEVD cleavage (Figure 1A),
and the expression of a cleaved caspases-3, -8 and -9 pro-
Plating efficiency, PE (number of clones counted in contro = l ls/number of cells plated)
Surviving fraction, SF [number of clones in treated well/( = n number of cells seeded PE)]. ´
TRAIL induced caspase activation in PC-3 cells does not lead to apoptosis Figure 1
TRAIL induced caspase activation in PC-3 cells does not lead to apoptosis. A. PC-3 cells were treated with TRAIL 
(25 ng/ml) for the indicated times. Caspase (DEVDase) activity was measured using a fluorometric assay as described in mate-
rials and methods with activity relative to control cells. B. Cells were treated with TRAIL (25 ng/ml) for 3 hours. The expres-
sion levels of caspases -3, -8, and -9, and their cleaved products were detected by Western blotting. Data shown is 
representative of a minimum of three independent experiments. C. Apoptosis (%) was assessed by propidium iodide DNA 
staining and flow cytometry after 6 – 24 hours of TRAIL treatment in PC-3 cells. Treatment of TRAIL in combination with res-
veratrol was included at all time points as a positive control ((+)ve con) for apoptosis induction.Molecular Cancer 2009, 8:39 http://www.molecular-cancer.com/content/8/1/39
Page 5 of 12
(page number not for citation purposes)
tein as early as 3 hours (Figure 1B), however, this did not
result in a corresponding increase in cell death even at 24
hours (Figure 1C). Thus although TRAIL can initiate an
apoptotic signal in PC-3 cells, there is a block present
which prevents apoptosis going to completion. Activation
of caspases in the absence of cell death suggests that a pro-
tein or family of proteins may be over expressed in these
cells which inhibits the apoptosis pathway. IAPs are
known to inhibit apoptosis at the level of caspases, not
only inhibiting caspase activation but also interfering
with active caspases. Previous studies in our laboratory
have demonstrated that cIAP-1, cIAP-2 and XIAP are
expressed in the PC-3 cells [5].
siRNA mediated knockdown of cIAP1, cIAP2 and XIAP in 
PC-3 cells
In order to determine whether IAP knockdown could
increase sensitivity to apoptotic triggers, conditions were
optimised using a number of commercially available siR-
NAs. Optimisation experiments (data not shown) indi-
cated that 0.5 nM siRNA from Ambion was the optimal
concentration for efficient knockdown of cIAP-1, cIAP-2
and XIAP in these cells, achieving 60 – 70% reduction of
the target gene (Figure 2a). Furthermore, various combi-
nations of siRNAs to different targets did not lead to any
decrease in knockdown efficiency for each individual tar-
get. Knockdown of IAPs either individually or in combi-
nation was also determined at the level of protein by
western blotting (Figure 2b) which demonstrated signifi-
cant reduction in the specific targeted protein.
Combined knockdown is required to sensitise PC-3 cells to 
TRAIL induced cell death
Following IAP knockdown, cells were treated with TRAIL for
24 hours and cell viability and apoptosis were assessed by
flow cytometry. IAP knockdown alone had no effect on cell
viability or apoptosis levels as compared with cells trans-
fected with control siRNA (Figure 3). Upon TRAIL treatment
however, increased levels of cell death were observed in
response to IAP knockdown. Specifically, only combinations
of either cIAP-1 and XIAP siRNA, or siRNA to all three IAPs
led to a significant increase in cytotoxicity, demonstrated by
a small but significant increase in apoptosis levels (Figure
3B), and a drop in viability by up to 20% (Figure 3A). Of
siRNA mediated knockdown of cIAP1, cIAP2 and XIAP Figure 2
siRNA mediated knockdown of cIAP1, cIAP2 and XIAP. Cells were transfected with siRNA targeting cIAP-1 (0.5 nM), 
cIAP-2 (0.5 nM), XIAP (0.5 nM), or combinations thereof (indicated on x-axis in A, and above top panel in B), and correspond-
ing non-targeting control siRNA (siCon) to a final concentration of 1.5 nM for each group. 24 hour post-transfection, expres-
sion levels of targets were analysed at a gene level using real time PCR (A), and at protein level using Western blotting (B). Lipo 
= lipofectamine control.Molecular Cancer 2009, 8:39 http://www.molecular-cancer.com/content/8/1/39
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note, although there was a trend towards an increase in non-
viable and apoptotic cells following knockdown of XIAP
alone this did not reach significance. Thus individual knock-
down of IAPs does not sensitise PC-3 cells to TRAIL, but
combined knockdown is required.
To determine if the effect of IAP knockdown was specific
for TRAIL treatment, siRNA mediated knockdown of IAPs
was followed by treatment with either etoposide or tuni-
camycin, agents with distinct modes of action to TRAIL.
Like TRAIL, individual knockdown had no effect, how-
ever, combined knockdown also failed to increase sensi-
tivity (Figure 3C–F), as demonstrated by measuring
viability and apoptosis.
Increased cell death following IAP knockdown is caspase 
dependent and leads to increased PARP activation
As knockdown was causing a significant loss in viability
but only a small detectable increase in apoptosis at 24
hours, we next wanted to determine whether the observed
loss in viability was in fact late apoptosis. Initially cell
death was assessed by combining Annexin V with PI stain-
ing, followed by flow cytometry. As shown in Figure 4A
and 4B, this confirmed that combined knockdown of
cIAP-1, cIAP-2 and XIAP led to a significant increase in cell
death (PI/Annexin V +/+). While these cells are likely late
apoptosis, the possibility remained that they are necrotic.
To confirm that they were late-apoptosis, cells were incu-
bated with the pan-caspase inhibitor zVAD.fmk prior to
Combined IAP knockdown is required to sensitise PC-3 cells to TRAIL-induced death Figure 3
Combined IAP knockdown is required to sensitise PC-3 cells to TRAIL-induced death. Cells were transfected with 
siRNA targeting cIAP-1 (0.5 nM), cIAP-2 (0.5 nM), XIAP (0.5 nM), or combinations thereof (as indicated on x-axis), and corre-
sponding non-targeting control siRNA (siCon) to a final concentration of 1.5 nM for each group. 24 hour post-transfection 
cells were treated for a further 24 hours with TRAIL (25 ng/ml, A and B), Etoposide (10 μM, C and D), or Tunicmycin (2 μg/ml, 
E and F). Viability (A, C, E) and Apoptosis (B, D, F) were assessed by propidium iodide DNA staining and subsequent flow cyto-
metric analysis. Values are expressed as mean +/- SD. *Significantly different from cells transfected with non-targeting control 
(siCon) followed by treatment (TRAIL/Etop/Tm) at p < 0.01.Molecular Cancer 2009, 8:39 http://www.molecular-cancer.com/content/8/1/39
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TRAIL treatment (Figure 4C). Inhibition of caspase activ-
ity using zVAD.fmk completely inhibited the loss in via-
bility induced by TRAIL, thus demonstrating that
increased TRAIL induced apoptosis following combined
knockdown of IAPs, requires caspase activity. Further-
more, increased processing of the caspase substrate PARP
in response to TRAIL, was only observed in cells following
triple IAP knock down (Figure 4D).
IAP knockdown inhibits cell proliferation and clonogenic 
survival
IAPs have a number of additional pro-survival functions
that do not rely on direct apoptosis inhibition. cIAP1 has
been implicated as an oncogene [30] and the knock of
IAP's including Livin [31] and Survivin [32] inhibit prolif-
eration.
In this context we next wanted to determine if combined
IAP knockdown could alter long-term proliferation and
clonogenic survival of PC-3 cells. Cells were transfected
with siRNAs targeting the IAPs and levels of proliferation
were assessed using a crystal violet assay at 2, 3 and 5 day
intervals. Figure 5A demonstrates that combined knock-
down of IAPs in the absence of any further treatment is
sufficient to cause a consistent decrease in cell prolifera-
tion over the time-course examined, with almost 40%
decrease in proliferation compared with control at day 5
(Figure 5A). This effect was only seen on knockdown of all
Increased cell death following IAP knockdown due to apoptosis Figure 4
Increased cell death following IAP knockdown due to apoptosis. Cells were transfected with the combination of all 
three siRNAs targeting cIAP-1 (0.5 nM), cIAP-2 (0.5 nM), and XIAP (0.5 nM) (siTarget), or corresponding non-targeting control 
siRNA (0.5 nM of each control siRNA to a final concentration of 1.5 nM) (siCon). 24 hour post-transfection cells were treated 
with TRAIL (25 ng/ml) for a further 24 hours. Cell death was assessed by Annexin V/PI DNA staining and flow cytometry. A. 
Representative histograms following combined knockdown of all three IAPs (siTarget) +/- TRAIL treatment. B. Percent of cells 
in each quadrant (R1: PI/AV +/-, Necrotic; R2: PI/AV +/+, Late apoptotic/Necrotic; R3: PI/AV -/-, Live cells; R4: PI/AV -/+, Early 
apoptotic cells). Representative of three independent experiments. C. Cells were pre-treated with zVAD.fmk (100 μM) for 1 
hour prior to TRAIL treatment for 24 hours. Viability was assessed by PI-DNA staining and flow cytometry. D. Following 
TRAIL treatment for 9 hours, cell lysates were analysed for PARP processing by Western blot. Western shown is a represent-
ative of three independent western blots.Molecular Cancer 2009, 8:39 http://www.molecular-cancer.com/content/8/1/39
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three IAP in combination. Individual knockdown or
knockdown of two IAP in combination had no significant
effect on proliferation as demonstrated in Figure 5A which
is a representative of three separate experiments. Western
blot analysis was also carried out to assess the status of
gene knockdown over the course of a week. As demon-
strated in figure 5B, significant gene knockdown is main-
tained for 4 – 6 days. By day six, expression of IAPs started
to recover (Figure 5B). Thus transfection with siRNAs
leads to efficient knockdown of IAPs for up to a week and
corresponds to significant inhibition of cell proliferation.
As short-term knockdown of IAPs had a significant effect
on cell proliferation during the duration of knockdown,
we wished to investigate the impact on long term survival
of cells. Twenty four hours post-transfection cells were
reseeded in 6-well plates for clonogenic survival assays
and allowed to grow for approximately 2 weeks. Colonies
were subsequently stained and counted and clonogenic
survival was calculated. As shown in figure 6A and 6B,
there was a significant decrease in the numbers of colonies
as a result of IAP knockdown. Interestingly this effect was
only observed with combined knockdown with individ-
ual knockdown of the IAPs having little effect on long
term survival (data not shown). To further validate this
alteration in proliferation we looked at the expression lev-
els of the proliferation marker ID-1 following IAP knock-
down. IAP knockdown using siRNA lead to a decrease in
the protein expression levels of ID-1 (Figure 6C). Interest-
ingly, individual knockdown of ID-1 in the PC-3 cells had
no effect on clonogenic survival or proliferation (data not
shown) indicating that triple IAP knockdown may medi-
ate decreased proliferation through a number of mecha-
nisms, and does not act solely through ID-1.
Discussion
Androgen independent prostate cancer represents a signif-
icant clinical problem emerging 2–3 years after the com-
mencement of hormone ablation therapy. There is no
known cure for this progressive form of the disease but
manipulation of the resistant anti-apoptotic phenotype
has been proposed as a treatment strategy. Previous stud-
IAP knockdown inhibits proliferation Figure 5
IAP knockdown inhibits proliferation. A. Cells were transfected with siRNA targeting cIAP-1 (0.5 nM), cIAP-2 (0.5 nM), 
XIAP (0.5 nM), or combinations thereof (as indicated in insert), and corresponding non-targeting control siRNA (siCon) to a 
final concentration of 1.5 nM for each group. Cells were grown in 6-well plates from 2 – 6 days, and stained with crystal violet 
as described in methods. Cell number is expressed as percent of control at time 0 days. Results are a representative of three 
independent experiments. B. Cells were transfected with the combination of all three siRNAs targeting cIAP-1 (0.5 nM), cIAP-
2 (0.5 nM), and XIAP (0.5 nM) (siTarget), or corresponding non-targeting control siRNA (0.5 nM of each control siRNA to a 
final concentration of 1.5 nM) (siCon). Total cellular protein was extracted at days 2, 4 and 6 and western blot analysis of IAP 
knockdown was undertaken. Western blots are a representative of three individual experiments.Molecular Cancer 2009, 8:39 http://www.molecular-cancer.com/content/8/1/39
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ies have demonstrated that androgen independent pros-
tate cancer cells have elevated levels of a range of anti-
apoptotic proteins including the inhibitors of apoptosis
family of proteins (IAPs), which is the basis for targeting
these proteins in this study. Here we confirm that PC-3
cells have significant expression of cIAP-1, cIAP-2 and
XIAP as compared to PwR-1E and LNCaP cells [6,5] and
are highly resistant to TRAIL-induced apoptosis, as we
have previously demonstrated [29].
We have previously reported that pre-incubation of PC-3
cells with resveratrol significantly increases their sensitiv-
ity to TRAIL-induced apoptosis due to an inhibition of
AKT phosphorylation associated with altered IAP expres-
sion. This study clearly demonstrated that manipulation
of the survival signals within the cell can increase thera-
peutic responses, however targeted approaches and a clear
understanding of how they mediate their effects is
required. Despite PC-3 cell resistance to TRAIL induced
apoptosis we did demonstrate activation of caspase 8 and
3 activity. This is in keeping with recent studies by Hellwig
et al who have shown that a required threshold of caspase
activity must be reached before apoptosis can be induced
[33]. From this we hypothesised that decreasing the
expression of the inhibitors of apoptosis would remove
the block or lower the threshold required to allow TRAIL
to initiate apoptosis in PC-3 cells.
In keeping with this hypothesis we developed siRNA strat-
egies to simultaneously inhibit the expression of cIAP-1,
Short-term knockdown of IAPs decreases long-term survival Figure 6
Short-term knockdown of IAPs decreases long-term survival. Cells were transfected with the combination of all three 
siRNAs targeting cIAP-1 (0.5 nM), cIAP-2 (0.5 nM), and XIAP (0.5 nM) (siTarget), or corresponding non-targeting control 
siRNA (0.5 nM of each control siRNA to a final concentration of 1.5 nM) (siCon). A, B. 24 hour post-transfection cells were 
re-seeded for clonogenic assay as described in methods. Cells were grown until colonies formed (2 weeks), then stained, fixed 
and counted to determine surviving fraction. A. Representative image of colony formation in Control cells (non-targeting 
siRNA; siCon) and following combined IAP knockdown (siTarget). B. Clonogenic survival in IAP targeted cells. Surviving frac-
tion was calculated as described in methods and expressed as % survival. *p = 0.024 verses siRNA control (siCon), n = 4 indi-
vidual experiments. C. Expression of proliferation marker ID-1 following IAP knockdown as shown by Western blotting.Molecular Cancer 2009, 8:39 http://www.molecular-cancer.com/content/8/1/39
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cIAP-2 and XIAP, which were reduced to about 40% of
control levels as confirmed at both the mRNA and protein
level. This was not associated with any direct toxicity or
loss of cell viability within the early time points studied.
We clearly demonstrated that individual knockdown of a
single IAP had no effect on the expression levels of the
other two IAP. This is supported by Volger et al who
showed similar results when they individually knocked
down XIAP using retroviral short-hairpin RNA vector [34].
In contrast, other studies have shown that XIAP inhibition
causes up regulation of cIAP-1 and cIAP-2 [35]. We also
demonstrate that IAP knock down does not increase basal
apoptosis. Previously we have shown that anti-sense oli-
gonucleotide strategies to cIAP-1 did result in a significant
10% induction of basal apoptosis in PC-3 and DU-145
cells [15]. In addition, knock down of XIAP using anti-
sense did, by itself, result in a small but significant
decrease in cell viability in DU-145 cells [21]. We believe
that the differences observed in these studies and that of
the current study might be as a result of the strategies used
to knockdown the individual IAPs and the level of knock
down achieved. These other strategies may have effects
that are directly toxic to the target cells and thus on com-
bination with other triggers of apoptosis pushes them into
a death response.
Following confirmation of appropriate knock down we
demonstrate for the first time that triple knockdown of
cIAP-1, cIAP-2 and XIAP increases the sensitivity of PC-3
cells to TRAIL induced loss in viability and apoptosis as
compared to individual IAP knock down. This demon-
strates that the resistance to TRAIL induced apoptosis in
PC-3 cells is facilitated by all three IAPs. But, in fact we only
partially increased the sensitivity of these cells to apoptosis
indicating that other pathways are also involved. When we
compare the levels of apoptosis induced by the triple knock
down and TRAIL with a combination of Resveratrol and
TRAIL, as used in previous studies, the levels of apoptosis
are higher with Resveratrol pre-treatment (data not
shown). This is in keeping with the ability of resveratrol to
not only alter IAP expression but also to affect other sur-
vival pathways including AKT signalling [29].
Individual knock down of cIAP-1, cIAP-2 and XIAP did
not increase sensitivity to apoptosis despite previous stud-
ies demonstrating that the knock down of XIAP can
increase sensitivity to TRAIL and cisplatin induced apop-
tosis [21], and that knock down of cIAP-1 can sensitise for
Fas and TNFalpha induced apoptosis [15]. In our current
study, the next most effective combination was cIAP-1
and XIAP which resulted in significant induction of apop-
tosis and loss of viability following treatment with TRAIL.
Targeting IAPs either individually or in combination did
not increase sensitivity of the cells to Etoposide or Tunic-
mycin, treatments which where chosen on the basis that
their effects are partially mediated via disruption of mito-
chondrial or endoplasmic reticulum signalling [29]. This
suggests selectivity of this priming effect for the death
receptor and extrinsic cell death pathway, and is in keep-
ing with our previous study where cIAP-1 antisense
primed only for Fas and TNFalpha induced apoptosis but
not for paclitaxel induced apoptosis. In contrast, knock-
down of XIAP in DU145 cells has been shown to increase
sensitivity to cisplatin induced apoptosis and its knock-
down in other tumour cells has been shown to sensitise
for cytotoxic drugs such as mitomycin C, doxorubicin,
etoposide and taxanes [36]. This suggests not only cell-
type dependent effects but also treatment specific effects
in relation to individual or combinations of IAPs.
Having demonstrated that triple knock down increases
apoptosis and decreases viability in response to TRAIL we
next wanted to investigate the mechanisms involved. We
demonstrated that this effect is caspase dependent as there
is a significant increase in PARP cleavage, and the priming
effect could be prevented by pre-incubation with the pan-
caspase inhibitor ZVAD.fmk. This suggests that the thresh-
old level of caspase activation required to initiate apopto-
sis can be reached when cIAP-1, cIAP-2 and XIAP are
knocked down, an effect which is blocked by ZVAD.fmk.
IAPs have a number of additional pro-survival functions
that do not rely on direct apoptosis inhibition. cIAP-1 has
been implicated as an oncogene whereby it promotes
tumourogenesis in cooperation with Yap1 [30]. Similarly,
there is emerging evidence that knock down of IAPs
including Livin and Survivin inhibit proliferation. Down
regulation of Livin expression by RNAi in colorectal can-
cer cell lines significantly inhibited in vitro cell prolifera-
tion and in vivo tumorigenicity [31], while knock down of
the survivin gene induced growth inhibition, as well as
apoptosis, in Burkitt's lymphoma Raji cell line [32]. Oth-
ers have demonstrated that knockdown of XIAP strongly
inhibits clonogenicity of pancreatic cancer cells treated
with TRAIL indicating that XIAP promotes clonogenic sur-
vival of pancreatic carcinoma cells [34].
Another very important role for the IAP is in their regula-
tion of NF-κB. cIAP-1 acts as an E2 ubiquitin ligase for
nuclear factor-κB-inducing kinase (NIK) maintaining low
basal levels of NIK and preventing NF-κB signalling [37]
thus loss of cIAP-1 could result in NF-κB activation. This
contradictory role for cIAP-1 might well explain why IAP
knockdown does not sensitise for cytotoxic induced apop-
tosis with Etoposide. One hypothesis would be that IAP
knockdown could result in NF-κB activation and com-
bined with Etoposides stimulation of NF-κB result in
increased NF-κB activation, transcription of anti-apop-
totic proteins and survival of the cell. On the other hand,Molecular Cancer 2009, 8:39 http://www.molecular-cancer.com/content/8/1/39
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where TRAIL has also been shown to induce NF-κB activa-
tion as a survival signal this effect is dependent on NIK,
IKK1, IKK2 as well as TRAF2 [38]. As cIAP-1 binds to
TRAF2 it might prevent TRAIL induced NF-κB activation
resulting in increased susceptibility to apoptotic triggers
and begin to explain the specific effect of IAP knockdown
on TRAIL induced apoptosis.
In our current study, combined knockdown of cIAP-1,
cIAP-2 and XIAP was associated with a decreased rate of
proliferation as assessed by crystal violet growth assays.
More interesting, long term clonogenic assays also dem-
onstrated reduced colony formation after 2 weeks follow-
ing a transient knock down of cIAP-1, cIAP-2 and XIAP.
This study clearly demonstrates that manipulation of
these three IAP simultaneously has a direct effect on the
cells ability to proliferate and recover. To further under-
stand the mechanism involved we investigated the effects
of the triple knock down on ID-1 expression. ID-1 is a
member of the helix-loop-helix protein family and regu-
lates gene transcription with significant increases in activ-
ity in actively proliferating cells [39]. Associated with the
activation of NF-κB as a down stream target, it mediates a
number of functions from proliferation, survival, angio-
genesis and invasion leading to tumorigenesis, and repre-
sents an important oncogene [39]. Here ID-1 protein
expression was decreased following 24 hour simultaneous
knock down of cIAP-1, cIAP-2 and XIAP, with no effect of
individual IAP manipulation on its expression.
Conclusion
This study demonstrates that simultaneous knock down
of cIAP-1, cIAP-2 and XIAP primes PC-3 cells for TRAIL
induced apoptosis, an effect which is caspase dependent.
The inability to alter sensitivity to other triggers of apop-
tosis suggests that this effect is specific for death receptor
pathways. Thus IAP knock down might facilitate the
immune-surveillance mechanisms to counter cancer pro-
gression and, in combination with TRAIL or similar ther-
apeutics, could represent an important treatment strategy.
We have also shown that triple knock down has a direct
effect on cell colony formation and proliferation indicat-
ing a central role of the IAP in this function and suggesting
the potential benefits of targeting IAPs even in the absence
of other treatments.
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